Literature DB >> 15113906

CD4+ T cells from CD4C/HIVNef transgenic mice show enhanced activation in vivo with impaired proliferation in vitro but are dispensable for the development of a severe AIDS-like organ disease.

Xiaoduan Weng1, Elena Priceputu, Pavel Chrobak, Johanne Poudrier, Denis G Kay, Zaher Hanna, Tak W Mak, Paul Jolicoeur.   

Abstract

The cellular and molecular mechanisms of dysfunction and depletion of CD4+ T lymphocytes over the course of human immunodeficiency virus type 1 (HIV-1) infection are still incompletely understood, but chronic immune activation is thought to play an important role in disease progression. We studied CD4+ T-cell biology in CD4C/HIV transgenic (Tg) mice, in which Nef expression is sufficient to induce a severe AIDS-like disease including a preferential decrease of CD4+ T cells. We show here that Nef-expressing Tg CD4+ T cells exhibit an activated/memory-like phenotype which appears to be independent of antigenic stimulation, as documented in experiments involving breeding with AD10 TcR Tg mice. In addition, in vivo bromodeoxyuridine incorporation showed that a larger proportion of Tg than non-Tg CD4+ T cells entered the S phase. However, in vitro, Tg CD4+ T cells were found to have a very limited capacity to divide in response to stimulation with anti-CD3 and anti-CD28 or in allogeneic mixed leukocyte reactions. Interestingly, despite these observations, the deletion of Tg CD4+ T cells had little impact on the development of other AIDS-like organ phenotypes. Thus, the Nef-induced chronic activation of CD4+ T cells may exhaust the T-cell pool and may contribute to the thymic atrophy and the low number of CD4+ T cells observed in these Tg mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113906      PMCID: PMC400335          DOI: 10.1128/jvi.78.10.5244-5257.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  A proposed mechanism for the induction of activator protein 1 (AP-1) binding by HIV-1 negative factor(Nef) in the macrophage cell line RAW267.4 cells.

Authors:  T Biggs; C Barton; D Mann
Journal:  Biochem Soc Trans       Date:  1998-08       Impact factor: 5.407

2.  Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys.

Authors:  Z Du; S M Lang; V G Sasseville; A A Lackner; P O Ilyinskii; M D Daniel; J U Jung; R C Desrosiers
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

3.  Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.

Authors:  Z Hanna; D G Kay; N Rebai; A Guimond; S Jothy; P Jolicoeur
Journal:  Cell       Date:  1998-10-16       Impact factor: 41.582

4.  Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS.

Authors:  M T Roos; M Prins; M Koot; F de Wolf; M Bakker; R A Coutinho; F Miedema; P T Schellekens
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

5.  Physical and functional interaction of Nef with Lck. HIV-1 Nef-induced T-cell signaling defects.

Authors:  Y Collette; H Dutartre; A Benziane; R Benarous; M Harris; D Olive
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

6.  Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines.

Authors:  A Greenway; A Azad; D McPhee
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 7.  Immunopathogenic mechanisms of HIV infection.

Authors:  A S Fauci; G Pantaleo; S Stanley; D Weissman
Journal:  Ann Intern Med       Date:  1996-04-01       Impact factor: 25.391

8.  Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity.

Authors:  A Greenway; A Azad; J Mills; D McPhee
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization.

Authors:  A S Baur; E T Sawai; P Dazin; W J Fantl; C Cheng-Mayer; B M Peterlin
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

10.  Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.

Authors:  N J Deacon; A Tsykin; A Solomon; K Smith; M Ludford-Menting; D J Hooker; D A McPhee; A L Greenway; A Ellett; C Chatfield; V A Lawson; S Crowe; A Maerz; S Sonza; J Learmont; J S Sullivan; A Cunningham; D Dwyer; D Dowton; J Mills
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

View more
  11 in total

1.  Intracellular Nef detected in peripheral blood mononuclear cells from HIV patients.

Authors:  Ting Wang; Linden A Green; Samir K Gupta; Tohti Amet; Daniel J Byrd; Qigui Yu; Homer L Twigg; Matthias Clauss
Journal:  AIDS Res Hum Retroviruses       Date:  2014-09-04       Impact factor: 2.205

2.  The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.

Authors:  Elena Priceputu; Isabelle Rodrigue; Pavel Chrobak; Johanne Poudrier; Tak W Mak; Zaher Hanna; Chunyan Hu; Denis G Kay; Paul Jolicoeur
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.

Authors:  Elena Priceputu; Zaher Hanna; Chunyan Hu; Marie-Chantal Simard; Patrick Vincent; Steffen Wildum; Michael Schindler; Frank Kirchhoff; Paul Jolicoeur
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

4.  Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes.

Authors:  Zaher Hanna; Elena Priceputu; Pavel Chrobak; Chunyan Hu; Véronique Dugas; Mathieu Goupil; Miriam Marquis; Louis de Repentigny; Paul Jolicoeur
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

5.  Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene.

Authors:  Kassandre Leongson; Vincent Cousineau-Côté; Mathieu Goupil; Francine Aumont; Serge Sénéchal; Louis Gaboury; Paul Jolicoeur; James W Kronstad; Louis de Repentigny
Journal:  Infect Immun       Date:  2013-01-22       Impact factor: 3.441

Review 6.  Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.

Authors:  Ting Wang; Ru Yi; Linden Ann Green; Sarvesh Chelvanambi; Michael Seimetz; Matthias Clauss
Journal:  Cardiovasc Pathol       Date:  2015-07-09       Impact factor: 2.185

7.  Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia.

Authors:  Mir Munir Ahmed Rahim; Pavel Chrobak; Chunyan Hu; Zaher Hanna; Paul Jolicoeur
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

8.  Repeated stimulation of CD4 effector T cells can limit their protective function.

Authors:  Dawn M Jelley-Gibbs; John P Dibble; Svetlana Filipson; Laura Haynes; Roslyn A Kemp; Susan L Swain
Journal:  J Exp Med       Date:  2005-03-28       Impact factor: 14.307

Review 9.  Oropharyngeal Candidiasis in HIV Infection: Analysis of Impaired Mucosal Immune Response to Candida albicans in Mice Expressing the HIV-1 Transgene.

Authors:  Louis de Repentigny; Mathieu Goupil; Paul Jolicoeur
Journal:  Pathogens       Date:  2015-06-23

10.  Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene.

Authors:  Mathieu Goupil; Vincent Cousineau-Côté; Francine Aumont; Serge Sénéchal; Louis Gaboury; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  BMC Immunol       Date:  2014-10-26       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.